Contents

Volume 80 Issue 7 | ARD July 2021

Editorial
823 Tenascin-C, a novel target to inhibit new bone formation in axial spondyloarthritis, linked with inflammation, mechanical strain and tissue damage
M Van Mechelen, R Lories

Thinking the unthinkable
825 Rheumatoid in 2049: the age of all data
J Mucke, P Sewerin, M Schneider

Review
828 Tissue physiology revolving around the clock: circadian rhythms as exemplified by the intervertebral disc
H Morris, C F Goncalves, M Dudek, J Hoyland, Q J Meng

Recommendation
840 EULAR recommendations for the reporting of ultrasound studies in rheumatoid and musculoskeletal diseases (RMDs)

Rheumatoid arthritis
848 Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Systemic sclerosis
859 Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PrECARA study
H TW Smeenk, E Roeder, H M Windjes, L JC Kranenburg-van Koppen, J AMW Hazes, R JEN Dolfhain

865 JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
P G Traves, B Murray, F Campigotto, R Galien, A Meng, J A Di Paolo

876 Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD4+ T cells through differential DNA methylation, explaining a substantial proportion of heritability
E Ha, S-Y Bang, J Lim, J H Yun, J-M Kim, J-B Bae, H-S Lee, B-J Kim, K Kim, S-C Bae

Inflammatory arthritis
884 Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis
I Gessl, M Popeva, V Schimpf, G Supp, T Deimel, M Durechova, M Huckle, M Loiskandl, P Studenic, M Zauner, J S Smolen, D Aletaha, P Mandl

Spondyloarthritis
891 Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes enthesal new bone formation through activation of Hippo signalling in ankylosing spondylitis
Z Li, S Chen, H Cai, X Li, D Chen, W Hao, J Wang, Z Li, Z Zheng, Z Zhong, H Liu

Pain
903 Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study)

Systemic sclerosis
912 Autoantibodies targeting telomere-associated proteins in systemic sclerosis
B I Adler, F Bon, J P Wolbers, C O Bingham, A A A Shaf, C Greider, L Casciola-Rosen, A Rosen

Disclaimer: The Editor of ARD has been granted editorial freedom and ARD is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. ARD is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by ARD does not imply endorsement. Neither EULAR nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from ARD (except for liability which cannot be legally excluded).

Copyright: © 2021 BMJ Publishing Group Ltd and European Alliance of Associations for Rheumatology. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd through its editor, Exter Press Media Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN 0003-4967 (USPS 21512) is published monthly by BMJ Publishing Group Ltd, BMJ House, Tavistock Square, WC1H 9JR, London. Airfreight and mailing by World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256, USA. Postmaster: Send address changes to Annals of the Rheumatic Diseases, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMJ House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.
### Contents

**Volume 80 | Issue 7 | ARD July 2021**

#### Epidemiology

**930** Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry


#### Letters

**953** SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists

R Priori, G Pellegrino, S Colafrancesco, C Alessandri, F Cecarelli, M Di Franco, V Ricciari, R Servo, A Sili Zavattini, F R Spinelli, F Conti

**954** Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)

D J Wallace, F Figuera, W A Wegener, D M Goldenberg

**956** Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort: a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology

T Saeki, T Nagasewa, Y Ubara, Y Taniguchi, M Yanagita, S Niki, M Nagata, Y Yamaguchi, T Saito, H Nakanoshima, M Kawano

**957** Bone loss in patients with SAPHO syndrome: a preliminary study

X Chen, M Wang, W Cui, Z Wang

#### Electronic pages

**e103** Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study

J Imazio

**e104** Response to: 'Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Imazio

D Alpizar Rodriguez, T R Lester, B Gilbert, T Streng, A Finch

**e105** Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease

S-W Lai, Y-H Kao, K-F Liao

**e106** Response to: 'Chronic hydroxychloroquine exposure and the risk of Alzheimer’s disease' by Lai et al

L Fardet, I Petersen, J Nazareth

**e107** MS score in systemic juvenile idiopathic arthritis: suitable for routine use?

H Chi, Z Wang, C Yang, Y Su

**e108** Response to: 'MS score in systemic juvenile idiopathic arthritis: suitable for routine use?' by Chi et al

F Minovia, A Ravelli

**e109** Correspondence to 'Time to change the primary outcome of lupus trials'

S Oon, M Huq, M Nikpour

**e110** Response to Correspondence to 'Time to change the primary outcome of lupus trials' by Oon et al

F A Houssiau
Contents

Volume 80
Issue 7 | ARD July 2021

e111 Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren’s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren’s syndrome?
G Coiffier, A Martel, J-D Albert, A Lescoat, A Bleuzen, A Perdriger, M De Bandt, F Maillot

e112 Response to: ‘Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren’s syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren’s syndrome?’ by Coiffier et al

e113 Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis
C Campochiaro, G De Luca, M De Santis

e114 Response to: ‘Anti-Ku syndrome with elevated CK: association with myocardial involvement in systemic sclerosis’ by Campochiaro et al
L Spielmann, F Sèvres, A Meyer

e115 Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’
M Infantino, M Manfredi, N Bizzaro

e116 Response to: ‘Comment on: standardisation of myositis-specific antibodies: where are we today?’ by Infantino et al
J Rönnelid, F Espinosa-Ortega, I E. Lundberg

e117 Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype
L Gupta, S Ahmed, B Singh, S Prakash, S Phadke, A Aggarwal

e118 Response to: ‘Novel NLRP12 variant presenting with familial cold autoimmunity syndrome phenotype’ by Gupta et al
C Eijkelboom, N M Ter Haar, J Frenkel, M Gattorno

e119 How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
I Parodis, M Nikpour

e120 Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
E Raschi, I C Antonazzo, E Poluzzi, F De Ponti

e121 Aortic dilatation in a patient with Takayasu arteritis treated with tocilizumab
F Muratore, C Salvatoni